Android app on Google Play

Viropharma (VPHM) Shares Sink Amid Cinryze Data; Stifel Nicolaus Weighs In

March 6, 2012 12:46 PM EST Send to a Friend
Get Alerts VPHM Hot Sheet
Price: $49.96 --0%

Rating Summary:
    7 Buy, 13 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 2 | New: 6
Trade VPHM Now!
Join SI Premium – FREE
Shares of Viropharma (Nasdaq: VPHM) have tumbled nearly 7 percent Tuesday following the release of data on the company's subcutaneous Cinryze(R) with recombinant human hyaluronidase. The stock last traded at $30.50.

Stifel Nicolaus' Stephen Willey said in an earlier note Viropharma will likely need to show more dose-ranging data on the product's effectiveness. While the analyst noted 2,000-unit sub-Q data validates utilization of rHuPH20 usage with Cinryze, he warned logistical issues may pop up related to manufacturing capacity and cost before a twice-per-week dosing could be a feasible option. Willey also suggested the data confirms an unformulated sub-Q1 C1 inhibitor would not be a viable treatment option.

Despite the cautious comments, Stifel Nicolaus and Willey maintain a Buy rating and $42 price target on shares of Viropharma.

Visit our Analyst Ratings page to track all the market-moving analyst action on shares of Viropharma.

You May Also Be Interested In

Related Categories

Analyst Comments, Corporate News

Related Entities

Stifel Nicolaus

Add Your Comment